Molecule Holdings Inc.
EVRRF · OTC
7/31/2023 | 4/30/2023 | 1/31/2023 | 10/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | 0.01 | -0.01 |
| FCF Yield | -4.89% | -15.06% | -5.18% | 2.44% |
| EV / EBITDA | -25.59 | -17.59 | -12.01 | -7.25 |
| Quality | ||||
| ROIC | -118.62% | -35.53% | -63.65% | -83.94% |
| Gross Margin | 34.98% | 1.43% | -34.51% | -111.88% |
| Cash Conversion Ratio | 0.01 | 0.16 | 0.10 | -0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 76.55% | 198.50% | 1,280,458.63% | 1,253,149.78% |
| Free Cash Flow Growth | 92.52% | -51.24% | -186.19% | 129.25% |
| Safety | ||||
| Net Debt / EBITDA | -24.91 | -15.65 | -9.58 | -4.46 |
| Interest Coverage | -0.79 | -2.07 | -3.95 | -10.91 |
| Efficiency | ||||
| Inventory Turnover | 1.45 | 0.24 | 1.09 | 1.77 |
| Cash Conversion Cycle | -285.20 | -611.63 | -178.77 | -43.16 |